U.S., Jan. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07325136) titled 'A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer' on Jan. 06.
Brief Summary: The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Nivolumab in participants with Relapsed/Refractory Small Cell Lung Cancer
Study Start Date: Feb. 18
Study Type: INTERVENTIONAL
Condition:
Relapsed/Refractory Small Cell Lung Cancer
Intervention:
DRUG: BMS-986525
Specified dose on specified days
DRUG: Nivolumab
Specified dose on specified days
Recruitment Status: NOT_YET_RECRUI...